NDAORALTABLET
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
IBRANCE (palbociclib) by Pfizer is kinase inhibitors [moa]. First approved in 2019.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IBRANCE (palbociclib) is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that works by slowing cancer cell growth and division. It is indicated for hormone receptor-positive, HER2-negative breast cancer in combination with endocrine therapy. The drug represents a small-molecule targeted approach to precision oncology in hormone-sensitive malignancies.
$2.0BPart D
Peak10.4 years to LOEIBRANCE is at peak lifecycle stage with substantial commercial investment; Commercial teams are fully resourced and focused on market penetration and retention strategies.
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Started Oct 2026
40 enrolled
Breast CancerDiabetes Type II
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Started Nov 2025
25 enrolled
Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
Started Jun 2025
1 enrolled
Advanced or Metastatic Breast Cancer
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Started Feb 2025
54 enrolled
Well Differentiated LiposarcomaDedifferentiated LiposarcomaLiposarcoma+6 more
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Started Jan 2025
95,637 enrolled
Breast Neoplasms
Worked on IBRANCE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.